Xyotax Fails To Show Survival Benefit Again; CTI Continues To Tout Safety Profile
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
CTI’s repeated STELLAR trial failures to show Xyotax survival benefit for lung cancer could delay NDA submission. Detailed STELLAR 2 and 4 data showing equivalent survival with significant reductions in side effects compared to docetaxel or gemcitabine/vinorelbine will be presented in July